Predicting Tumor Heterogeneity Evolution After Therapy In Patient-Derived Ex Vivo Glioblastoma Organoids


Year of Award:
2018
Status:
Active
Award Type:
R21
Project Number:
CA229027
RFA Number:
RFA-CA-17-012
Technology Track:
Biospecimen Science Technologies
PI/Project Leader:
SKARDAL, ALEKSANDER (contact); STROWD, ROY ERVIN
Institution:
WAKE FOREST UNIVERSITY HEALTH SCIENCES
PROJECT SUMMARY Glioblastoma (GBM) is a lethal, incurable form of cancer in the brain. Even with maximally aggressive surgery and chemoradiotherapy, median survival is 14.5 months. These tumors infiltrate normal brain tissue, are surgically incurable, and